mmpc-logo mmpc-logo
twitter-logo    bluesky-logo
| Create Account | login
Publication
Injection Reactions after Administration of Sustained-release Meloxicam to
BALB/cJ, C57BL/6J, and Crl:CD1(ICR) Mice.
Authors Fuetsch SR, Stewart LA, Imai DM, Beckett LA, Li Y, Lloyd KCK, Grimsrud KN
Submitted By Submitted Externally on 12/3/2021
Status Published
Journal Journal of the American Association for Laboratory Animal Science : JAALAS
Year 2021
Date Published 3/1/2021
Volume : Pages 60 : 176 - 183
PubMed Reference 33402233
Abstract The sustained-release formulation of meloxicam (MSR) is a compounded NSAID that
may provide pain relief for as long as 72 h after administration. MSR
injection-site skin reactions have occurred in several species but have not
previously been observed in mice. We investigated the development and
progression of localized skin reactions after a single injection of MSR in
Crl:CD1(ICR), C57BL/6J, and BALB/cJ mice. Each mouse received a subcutaneous
injection of MSR (n = 60), standard-formulation meloxicam (MEL; n = 24) or
saline (control; SC; n = 24) and was scored daily according to a 5-point system
for erythema and mass characteristics. Mice were euthanized at either 7 or 14 d
after injection and underwent postmortem analysis. MSR-treated mice had more
erythematous and mass reactions than did MEL and SC mice. Mass lesions developed
in 49 MSR mice (82%; 95% CI, 70% to 90%), 5 MEL animals (21%; 95% CI, 7% to
42%), and 1 SC mouse. MSR-treated BALB/cJ developed erythematous lesions less
frequently than similarly treated Crl:CD1(ICR) or C57BL/6J. Lesions often were
ventrolateral to the injection site. The median times to the appearance of mass
and erythematous lesions were 2 d and 3 d, respectively. Histologically, the
erythematous and mass reactions correlated with necrotizing to pyogranulomatous
injection-site panniculitis. Inflammation severity scores at 7 and 14 d after
injection were greater in the MSR-treated group than the other 2 groups. No
strain- or sex-associated differences emerged except that inflammation severity
scores at day 14 were higher in Crl:CD1(ICR) females than males. The character
of the inflammatory response in MSR-treated mice did not differ between 7 and 14
d after injection, indicating that MSR-induced inflammation is slow to resolve.
The ventral migration and delayed onset of MSR injection-site reactions could
result in their being attributed to another cause or not being identified.
Researchers and clinicians should be aware of the potential for slowly resolving
injection-site reactions with MSR.




Menu

Home
Contact
About MMPC
Animal Husbandry
Tests Data
Search Data
Analysis
Clients
MMPC Centers

Newsletter

Interested in receiving MMPC News?
twitter-logo Mouse Phenotyping
@NationalMMPC



2017 National MMPC. All Rights Reserved.